Skip to content
Search AI Powered

Latest Stories

The FDA Is Now Considering Ecstasy as a Therapy to Treat Veterans With PTSD

The FDA Is Now Considering Ecstasy as a Therapy to Treat Veterans With PTSD
MDMA, or Ecstasy pills, and powder and orange juice chaser. (Photo by Steve Liss/The LIFE Images Collection/Getty Images)

The FDA has announced that it is considering MDMA as a therapy to treat veterans with PTSD.

It is known by many names in popular culture: “hug drug,” “love drug,” “dance drug,” “ecstasy,” “XTC” and “Molly” — along with its scientific designation: MDMA. Now, the Food and Drug Administration (FDA) has bestowed an additional moniker: “breakthrough therapy.”

The FDA has announced that it is considering MDMA as a therapy to treat veterans with PTSD.


MDMA (or 3.4-methylenedioxymethamphetamine) has a convoluted history. It was first developed by a chemist working for the Merck pharmaceutical company in 1912, originally intended to combat abnormal bleeding conditions. Later, Merck explored whether MDMA would function similar to adrenaline or ephedrine since MDMA and ephedrine have similar chemical structures.

Declassified documents have shown that the United States military experimented with the drug in the 1950s as a possible “truth serum” with unspecified outcomes. In the mid-1960s, a psychopharmacologist synthesized MDMA during a series of experiments while working for Dow Chemical. This scientist did not investigate its psychoactive capabilities until hearing reports of its recreational use a decade later.

The first report of non-medical recreational use of MDMA was in the early 1970s. It seems that Chicago was the first epicenter of MDMA drug use in the nightlife scene, which eventually spread to California, and then on to rest of the United States and the globe.

In 1976, Alexander Shulgin, the chemist who synthesized MDMA in the 1960s for Dow Chemical, tried it on himself and recommended the compound to fellow psychopharmacologists and psychotherapists. Two years later, he published a paper with another chemist named David Nichols detailing how MDMA affects humans, describing that it “appears to evoke an easily controlled altered state of consciousness with emotional and sensual overtones. It can be compared in its effect to marijuana, to psilocybin devoid of the hallucinatory component.” The exploding popularity of MDMA as a party drug around the globe led to several countries to illegalize it and classify it as a Schedule 1 substance including Great Britain and the United States.

Enter the modern era, where MDMA is being investigated by the scientific community for its utility in treating a number of psychiatric conditions, most notably post-traumatic stress disorder (PTSD).

PTSD is a psychological condition that develops after an individual has experienced a severely traumatic event such as a car accident, near-death experience, warfare, or some form of assault. Symptoms usually persist for more than a month and can include but are not limited to: heightened “fight or flight” responses, severe avoidance of anything perceived as stressful, as well as emotional and physical distress when confronted with a potentially traumatic incident. Currently, only two drugs have been approved for treating PTSD (Paxil and Zoloft), which have unfortunately underperformed in alleviating PTSD for veterans. Thus, alternative treatments must be found to remedy the suffering of veterans afflicted with PTSD.

Fast forward to August of 2017: the FDA announced that it was classifying MDMA as a “breakthrough therapy” for the treatment of veterans experiencing PTSD.

The FDA rarely awards such a designation for substances that show “substantial improvement over existing therapies” in the treatment of severe conditions and diseases. This milestone was reached through the efforts of Rick Doblin, who founded the Multidisciplinary Association for Psychedelic Studies (or MAPS). The mission of this organization has been to harness the medical applications of marijuana and psychedelic drugs. MAPS secured funding for the Phase 2 clinical trials for MDMA’s use as a psychotherapy for US military veterans.

To prevent any possible bias, the clinicians used a double-blind for the Phase 2 clinical studies, so neither the doctors nor the patients were aware who was receiving MDMA and who was being given a placebo.

Over the course of several months, three doses were administered. The results were encouraging, where one study saw two-thirds of the patients fully recover from their PTSD. As many as 88 percent of individuals who received the MDMA treatments remained free of the symptoms of PTSD for over three years after receiving their final dose. The better-than-expected results of the Phase 2 trials led the FDA to approve large-scale Phase 3 studies in late 2016 with an anticipated start in early to mid-2018. These clinical investigations will be the final phase in getting the FDA to designate MDMA as a “prescription drug.” According to MAPS, the earliest date such an approval could be given would be as early as 2021.

MDMA is not the only psychoactive drug being researched for its benefits to people coping with PTSD and a host of other psychological conditions.

Indeed, there have been very recent reports championing hallucinogenics like LSD and psilocybin mushrooms for treating PTSD.  Beyond just PTSD, the use of psychedelic drugs such as MDMA and psilocybin has also been touted for palliative care in the treatment of those suffering from terminal ailments. It seems that MDMA has come full circle with regard to its therapeutic potential as in the 1970s when it was being promulgated by the psychiatric community as a drug capable of alleviating a variety of psychiatric conditions.

Despite all the research now showing its vast potential to help ameliorate multiple anxiety disorders, the stigma of it being nothing more than a “rave drug” for electronic music gatherings persists and with a significant amount of skepticism.

Indeed, the director of the Langone School of Medicine at New York University, Dr. Charles R. Marmar recently remarked that MDMA is “a feel-good drug, and we know people are prone to abuse it” after learning of the FDA green light for Phase 3 clinical trials. Still, MAPS scientists contend that the euphoric effect of the drug is what allows PTSD patients to circumvent mental barriers and confront the sources of their profound anxiety. The future utility of psychedelic drugs for medical use depends on the outcome of the current clinical trials, though the momentum seems to be on the side of the scientists and doctors committed to their therapeutic applications.

More from News

Jeff Ross
Mike Coppola/Variety via Getty Images

Comedian Jeff Ross Shares Photos Of Puffed Up Lip After Allergic Reaction To Ice Cream

Insult comic Jeff Ross revealed he had a medical emergency after a show Saturday night that resulted in a trip to the ER. However, he assured fans the show must go on despite "looking like Mickey Rourke at the end of The Wrestler."

Ross recounted the ordeal on Instagram, showing his swollen lip taking over his face from eating burrata ice cream after his Take a Banana for the Ride show in Mill Valley, California, near San Francisco.

Keep ReadingShow less
screenshot of Jesse Watters on Fox News
Fox News

Jesse Watters Offers Mind-Numbing New Claim About Masculinity—And Is Instantly Dragged

Problematic Fox News MAGA pundit Jesse Watters has made another bizarre claim about masculinity.

Having already taken exception with eating ice cream, drinking milkshakes, and taking bubble baths, Watters is now targeting tech jobs.

Keep ReadingShow less
Donald Trump with the Dodgers
Kevin Dietsch/Getty Images

Trump Leaves Everyone Confused With Hilariously Bizarre Word Salad Tribute To The Dodgers

President Donald Trump was widely mocked after he welcomed the 2024 World Series-winning Los Angeles Dodgers to the White House on Monday with a bizarre, tangential, and rambling speech.

The team arrived at the White House on Monday morning, where Trump, in his remarks, praised two-way star Shohei Ohtani and infielder Mookie Betts. The Dodgers had defeated the New York Yankees in five games to clinch their second World Series title in five seasons.

Keep ReadingShow less
Donald Trump
Kevin Dietsch/Getty Images

Trump Roasted After Giving Clunky New Nickname To People Criticizing His Tariffs

President Donald Trump was criticized after he pushed back against critics of his tariffs, coming up with a new nickname for the "weak and stupid" people who oppose them.

The Trump administration’s newly imposed tariffs on imports from various countries have unsettled consumers, triggered a trade war, disrupted global markets, and sparked widespread fears of a potential recession in the U.S. and beyond.

Keep ReadingShow less

Childhood Experiences People Thought Were 'Normal' But Weren't At All

Content Warning: Child neglect, child abuse, narcissism, gaslighting, people-pleasing, and other traumatic childhood experiences

It's important for us to work on ourselves, to continue bettering ourselves throughout our limited time on this earth, and a key way of doing that is acknowledging what we do not know, and working on that.

Keep ReadingShow less